The presence of the enzalutamide-agonistic F876L mutation and the presence of dominant AR splice variants limited our ability to test for the efficacy of combined AKT and MEK inhibition together with AR inhibition in advanced prostate cancer models. The gene discussed is MAP2K7; the disease is prostate carcinoma.